Pharmacokinetics of Benzbromarone in Normal Chinese Males

JU-YU HSU¹, MEI-YU HSU², HSING-CHU HSU^3*, SU-JONG CHEN³ AND I-PANG WANG³

1. Sidney Kimmel Cancer Center, 10835, Altman Row, Suite 240, San Diego, CA 92121, U.S.A.
2. Thomas Jefferson University Hospital, 1015 Walnut Street, Philadelphia, PA 19107-5099, U.S.A.
3. Chia Nan College of Pharmacy and Science, 60, Al-jen Rd., Sect. 1, Pau-an, Jen-teh hsiang, Tainan hsien, Taiwan, R.O.C.

ABSTRACT

   Pharmacokinetics of benzbromarone, a potent hypo-uricemics, have been investigated employing 26 normal Chinese males. Following oral administration of 100 mg dose (Desuric 100 mg/tablet, Labaz France), the pharmacokinetics of benzbromarone based on plasma data were Cmax (3.51± 0.90μg/mL, mean ± SD), AUCt (0-14 h, 17.94 ± 4.53 μg.h/mL), total AUC (19.00 ± 4.73 μg.h/mL), Tmax (3.08± 1.15 h), terminal phase T1/2 (2.97±0.85 h), MRT (5.70 ± 1.25 h) and Cl/F (89.5 ± 26.2 mL/min). Wagner-Nelson absorption plots of the mean benzbromarone plasma concentrations suggest that there are competing reactions in the absorption process. The 90% confidence regions for Cmax and AUC, and for Cmax , AUC and MRT, and their log-transformed vectors were also estimated. No evidence to show that the pharmacokinetics of benzbromarone in Chinese are different from those reported in Caucasian subjects, and none of the slow elimination phenotype with benzbromarone have been observed in this study.

Key words: benzbromarone, HPLC, pharmacokinetics, Chinese